Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms INCA-035784, INCA035784 |
Target |
Action inhibitors, stimulants |
Mechanism CALR inhibitors(calreticulin inhibitors), CD3 stimulants(T cell surface glycoprotein CD3 stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Myeloproliferative Disorders | Phase 1 | United States | 01 Oct 2025 | |
| Myeloproliferative Disorders | Phase 1 | Australia | 01 Oct 2025 |






